Reports
Reports
Sale
The global breast lesion localization methods market size was valued at USD 278.7 million in 2022, driven by the emphasis on preventing the increasing cases of breast cancer across the globe. The market is expected to grow at a CAGR of 4.8% during the forecast period of 2023-2031, with the values likely to rise from USD 292 million in 2023 to USD 425 million by 2031.
A breast lesion refers to the presence of an abnormal tissue or lump in the breast area. It can be a single or cluster of lumps. Although most lesions are benign (non-cancerous), some might turn out to be malignant (cancerous), hence, early detection is highly imperative. Symptoms for benign breast lesion may include pain in the affected area, fatigue, discomfort or loss of weight and appetite. Whereas changes in breast size, swelling or hardened area inside the underarm or breast are common indicators of malignant breast lesions.
Locating these lesions is extremely crucial in order to get a timely treatment. A breast lesion can be found through a self or clinical exam, which can be later confirmed using an imaging test. Diagnostic methods commonly constitute mammograms, magnetic resonance imaging (MRI), computed tomography (CT) scans, and ultrasounds.
With the rising prevalence of breast cancer, the number of surgeries has been on a rise. When compared to mastectomy, the frequency of breast-conserving (lumpectomy) surgery is higher. This is because it only removes the area of tumour and allows faster recovery as well. Since, these tumours are non-palpable, they require localization, which can be done through an ultrasound or mammography. As a result, the breast lesion localization methods market value has increased over the years.
Over the years, wire guided localization (WGL) has been commonly used for the surgical excision of a non-palpable breast lesion. This can be accredited to its low cost, high efficacy, and ease of accessibility. However, owing to several logistical challenges like its placement, patient discomfort and a possibility of wire dislocation, breast surgeons have showed their preference for other techniques like radioactive seed localization, radio-occult lesion localization (ROLL), and intraoperative ultrasound. As a result, the market for breast lesion localization has been evolving and welcoming new developments.
New localization devices like SAVI SCOUT®, Localizer™, Molli™, Magseed®, EnVisio®, and Pintuition® have flourished the market. MELODY (Methods for Localization of Different types of breast lesions) is another initiative launched by the European Breast Cancer Research Association of Surgical Trialists and the iBRA-NET. It allows the study of breast localization techniques and devices from various perspectives by enrolling a cohort of breast cancer patients, undergoing breast-conserving surgery using imaging-guided localization. Such initiatives indicate that we can observe breast lesion localization methods market growth in the upcoming years.
Market Breakup by Product Type
Market Breakup by Technique
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region- 7MM
The occurrence of breast cancer has been more common than lung cancer. Approximately, 297,790 women in the United States alone are estimated to be diagnosed with lung cancer in 2023. As a result, Unites States holds the largest breast lesion localization methods market share. With a high-tech infrastructure and the presence of major universities and healthcare industry pioneers, there has been significant emphasis on bringing quality diagnostics and treatments for the patients. Moreover, WHO recently released a Global Breast Cancer Initiative Framework that provides a roadmap to save around 2.5 million lives from breast cancer by 2040.
In addition, India partnered with the United States to develop an artificial intelligence (AI)-enabled digital pathology platform that will enable better diagnosis and prediction of therapeutic benefits to the patients. The US-India cancer dialogue also aims to bring the public and private sector that envisions around data sharing and synthetic biology.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2022 |
Historical Period | 2016-2022 |
Forecast Period | 2023-2031 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product Type |
|
Breakup by Technique |
|
Breakup by Application |
|
Breakup by End User |
|
Breakup by Region- 7MM |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Breast Lesion Localization Methods Market Overview
3.1 Breast Lesion Localization Methods Market Historical Value (2016-2022)
3.2 Breast Lesion Localization Methods Market Forecast Value (2023-2031)
4 Breast Lesion Localization Methods Market Landscape
4.1 Breast Lesion Localization Methods Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Breast Lesion Localization Methods Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Type
4.2.3 Analysis by Applications
5 Breast Lesion Localization Methods Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Breast Lesion Localization Methods Market Segmentation
6.1 Breast Lesion Localization Methods Market by Product Type
6.1.1 Market Overview
6.1.2 Localization Wires
6.1.3 Radioactive Seeds
6.1.4 Magnetic Tracers
6.1.5 Others
6.2 Breast Lesion Localization Methods Market by Technique
6.2.1 Market Overview
6.2.2 Wire Localization
6.2.3 Radioactive Seed Localization
6.2.4 Magnetic Tracers
6.2.5 Others
6.3 Breast Lesion Localization Methods Market by Application
6.3.1 Market Overview
6.3.2 Diagnostic
6.3.3 Therapeutic
6.4 Breast Lesion Localization Methods Market by End User
6.4.1 Market Overview
6.4.2 Diagnostic Centres
6.4.3 Hospitals
6.4.4 Oncology Clinics
6.4.5 Ambulatory Surgical Centres
6.4.6 Others
6.5 Breast Lesion Localization Methods Market by Region- 7MM
6.5.1 Market Overview
6.5.2 United States
6.5.3 EU-4 and the United Kingdom
6.5.4 Japan
7 United States Breast Lesion Localization Market
7.1 U.S. Breast Lesion Localization Market Historical Size (2016-2022)
7.2 U.S. Breast Lesion Localization Market Forecast Size (2023-2031)
7.3 Market Size by Therapeutic Class
8 EU-5 and the United Kingdom Breast Lesion Localization Market
8.1 EU-5 and the United Kingdom Breast Lesion Localization Market Historical Size (2016-2022)
8.2 EU-5 and the United Kingdom Breast Lesion Localization Market Forecast Size (2023-2031)
8.3 Market Size by Therapeutic Class
9 Japan Breast Lesion Localization Market
9.1 Japan Breast Lesion Localization Market Historical Size (2016-2022)
9.2 Japan Breast Lesion Localization Market Forecast Size (2023-2031)
9.3 Market Size by Therapeutic Class
10 Patent Analysis
10.1 Analysis by Type of Patent
10.2 Analysis by Publication year
10.3 Analysis by Issuing Authority
10.4 Analysis by Patent Age
10.5 Analysis by CPC Analysis
10.6 Analysis by Patent Valuation
10.7 Analysis by Key Players
11 Grants Analysis
11.1 Analysis by year
11.2 Analysis by Amount Awarded
11.3 Analysis by Issuing Authority
11.4 Analysis by Grant Application
11.5 Analysis by Funding Institute
11.6 Analysis by NIH Departments
11.7 Analysis by Recipient Organization
12 Funding Analysis
12.1 Analysis by Funding Instances
12.2 Analysis by Type of Funding
12.3 Analysis by Funding Amount
12.4 Analysis by Leading Players
12.5 Analysis by Leading Investors
12.6 Analysis by Geography
13 Partnership and Collaborations Analysis
13.1 Analysis by Partnership Instances
13.2 Analysis by Type of Partnership
13.3 Analysis by Leading Players
13.4 Analysis by Geography
14 Regulatory Framework
14.1 Regulatory Overview
14.1.1 US FDA
14.1.2 EU EMA
14.1.3 JAPAN PMDA
15 Supplier Landscape
15.1 Boston Scientific Corporation
15.1.1 Financial Analysis
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisition
15.1.5 Certifications
15.2 BD
15.2.1 Financial Analysis
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisition
15.2.5 Certifications
15.3 Medtronic
15.3.1 Financial Analysis
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisition
15.3.5 Certifications
15.4 Abbott
15.4.1 Financial Analysis
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisition
15.4.5 Certifications
15.5 Cook
15.5.1 Financial Analysis
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisition
15.5.5 Certifications
15.6 Stryker
15.6.1 Financial Analysis
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisition
15.6.5 Certifications
15.7 Wright Medical Group N.V.
15.7.1 Financial Analysis
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisition
15.7.5 Certifications
15.8 Zimmer Biomet
15.8.1 Financial Analysis
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisition
15.8.5 Certifications
15.9 Smith+Nephew
15.9.1 Financial Analysis
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisition
15.9.5 Certifications
15.10 Boston Scientific Corporation
15.10.1 Financial Analysis
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisition
15.10.5 Certifications
15.11 Organogenesis Inc.
15.11.1 Financial Analysis
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisition
15.11.5 Certifications
15.12 Arthrex, Inc.
15.12.1 Financial Analysis
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisition
15.12.5 Certifications
15.13 Orthofix Medical Inc.
15.13.1 Financial Analysis
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisition
15.13.5 Certifications
15.14 Kubtec X-Ray
15.14.1 Financial Analysis
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisition
15.14.5 Certifications
15.15 Miltenyi Biotec GMBH
15.15.1 Financial Analysis
15.15.2 Product Portfolio
15.15.3 Demographic Reach and Achievements
15.15.4 Mergers and Acquisition
15.15.5 Certifications
15.16 Naviscan
15.16.1 Financial Analysis
15.16.2 Product Portfolio
15.16.3 Demographic Reach and Achievements
15.16.4 Mergers and Acquisition
15.16.5 Certifications
15.17 PerkinElmer Inc.
15.17.1 Financial Analysis
15.17.2 Product Portfolio
15.17.3 Demographic Reach and Achievements
15.17.4 Mergers and Acquisition
15.17.5 Certifications
15.18 Thermo Fisher Scientific, Inc.
15.18.1 Financial Analysis
15.18.2 Product Portfolio
15.18.3 Demographic Reach and Achievements
15.18.4 Mergers and Acquisition
15.18.5 Certifications
15.19 Merit Medical Systems
15.19.1 Financial Analysis
15.19.2 Product Portfolio
15.19.3 Demographic Reach and Achievements
15.19.4 Mergers and Acquisition
15.19.5 Certifications
16 Breast Lesion Localization Methods Market - Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Key Opinion Leaders (KOL) Insights (Additional Insight)
18 Company Competitiveness Analysis (Additional Insight)
18.1 Very Small Companies
18.2 Small Companies
18.3 Mid-Sized Companies
18.4 Large Companies
18.5 Very Large Companies
19 Payment Methods (Additional Insight)
19.1 Government Funded
19.2 Private Insurance
19.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 278.7 million in 2022, driven by the emphasis on preventing deaths associated with breast cancer across the globe.
The market is anticipated to grow at a CAGR of 4.8% during the forecast period of 2023-2031, likely to reach a market value of USD by 425 million by 2031.
The prevalence of breast cancer in women has surpassed lung cancer. When going through surgery, the preference for breast-conserving surgery (lumpectomy) is greater than mastectomy. As lumpectomy requires a breast lesion localization technique, the market demand has increased.
The transition from wire guided localization to radio-occult lesion localization (ROLL), radioactive seed localization, and intraoperative ultrasound is the current trend. Moreover, WHO has launched Global Breast Cancer Initiative Framework, focused on decreasing breast cancer mortalities. Similarly, there has been an India-US partnership to focus on AI enabled digital platforms.
Common types of products include localization wires, radioactive seeds, and magnetic tracers, among others.
It finds wide application in diagnostics and therapeutics.
Wire localization, radioactive seed localization, and magnetic tracers, among others are some of the techniques.
The major regions of the market include the United States, Japan, EU-4, and the United Kingdom.
End users in the market include hospitals, diagnostic centers, oncology clinics, and ambulatory surgical centers, among others.
Key players involved in the market are Boston Scientific Corporation, BD, Medtronic, Abbott, Cook, Stryker, Wright Medical Group N.V., Zimmer Biomet, Smith+Nephew, Boston Scientific Corporation, Organogenesis Inc., Arthrex, Inc., Orthofix Medical Inc., Kubtec X-Ray, Miltenyi Biotec GMBH, Naviscan, PerkinElmer Inc., Thermo Fisher Scientific, Inc., and Merit Medical Systems.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.